Genetic heterogeneity and clonal evolution in neuroblastoma by Mora, J et al.
Neuroblastoma (NB) is a paediatric cancer that arises from
precursor cells of the peripheral sympathetic nervous system. It is
clinically heterogeneous with at least 3 well recognized patterns of
disease: (a) widespread disease in infants that can spontaneously
regress without medical intervention; (b) local-regional (LR)
disease that may recur after surgery but does not metastasize to
bone or bone marrow; and (c) systemic disease with widespread
marrow and skeletal metastases that initially respond to cytotoxic
therapy but frequently become resistant to medical treatment. It is
generally believed that such diverse clinical behaviours result
from the capacity of these tumours to exploit their genetic
malleability to evolve and adapt. 
The study of the molecular genetics of NB in the last 2 decades has
elucidated several nonrandom genetic events associated with the
disease: allelic losses on chromosomes 1p, 11q, 14q, 9p, 9q, 2q, 3p,
4p and 18q implicating putative tumour suppressor genes; allelic
gains on chromosomes 17q, 18q, 1q, 7 and 5q, some related to
growth control genes; amplification of the oncogene MYCN; and
changes in the normal diploid chromosomal content (Brodeur et al,
1999). The clinical role of each of these genetic events and their
evolution during tumour progression are, however, largely unknown. 
Prior studies have shown that NB is a genetically heterogeneous
neoplasia (Brodeur, 1995). Progression or regression of the tumour
may correlate with specific genetic alterations of tumour cells
(Ambros et al, 1995). Chromosome 1p allelic imbalance is a
common finding in NB, with patterns of LOH correlating with
different categories of disease (Mora et al, 2000). These unique
regions of LOH are useful clonal markers of disease progression
and evolution (Mao et al, 1994). Hyperploid DNA index is a
common favourable prognostic factor in LR NB and could also be
used as clonal marker. 
Using strict criteria for tumour quality, attention to non-
neoplastic tissue contamination, microdissection to enrich tumour
cell content especially in treated tumour samples, and easily quan-
titated fluorescent-based technology, more accurate definition of
allelic imbalance among tumour subsets and their clonal evolution
is possible (Larson et al, 1997). In this report we use 1p allelic
analysis and DNA ploidy to evaluate clonal heterogeneity and
clonal selection in vivo. Our findings suggest that genetic hetero-
geneity is common within each NB, and that in vivo clonal selec-
tion occurs in the presence or absence of chemotherapy. 
MATERIALS AND METHODS 
Patient materials and clinical characteristics 
61 samples from 25 patients treated at MSKCC from 1987 to 1999
were studied. Cases were divided into 2 groups. Group 1 was
composed of 33 tumours in 12 patients in which multiple specimens
were obtained from the same patient without intervening chem-
otherapy and included 6 patients with specimens at different sites
obtained at the same surgical procedure, and 6 patients with tumours
sequentially sampled at recurrence (at diagnosis and recurrence in 4
patients, and following multiple recurrences in 2). Group 2 (25
tumours in 10 patients) consisted of paired-samples obtained at the
Genetic heterogeneity and clonal evolution in
neuroblastoma 
J Mora1,2, N-KV Cheung1 and WL Gerald2
1Departments of Pediatrics and 2Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA 
Summary Tumour heterogeneity and clonal evolution at the genetic level may explain the development of malignant or resistant disease during
clinical progression of neuroblastoma (NB). In this report we use 1p allelic analysis and DNA ploidy to evaluate clonal heterogeneity and clonal
selection in vivo. We studied a total of 69 tumours from 29 patients with NB. To evaluate tumour heterogeneity and clonal evolution in vivo we
used a panel of polymorphic allelic markers mapping to chromosome 1. 33 tumours from 12 patients (group 1) were obtained from different
sites during the same surgery or at sequential surgeries without intervening chemotherapy to evaluate genetic heterogeneity. Paired samples
from 10 patients (group 2) were used to evaluate clonal selection before and after chemotherapy. In 6 cases paired tumours and derived cell
lines were studied. Analysis of DNA ploidy changes by karyotype, FISH and flow cytometry was performed in 15 tumours from 6 multiply
recurred local-regional (LR) NB patients. Allelotype study revealed that 66% (8/12) of group 1 samples were heterogeneous, with distinct allelic
patterns in tumour samples separated by time or location. In group 2 allelic patterns were different in post-chemotherapy specimens in 60%
(6/10). DNA ploidy analysis showed that pre-chemotherapy samples contained 2 distinct ploidy clones, one diploid and one triploid, whereas all
post-chemotherapy tumor samples were 100% diploid. These findings suggest that NB exhibits a high degree of clonal heterogeneity and
clonal evolution occurs during the course of therapy and clinical progression. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: heterogeneity; neuroblastoma; clonal evolution; DNA ploidy 
182
Received 6 December 2000 
Revised 12 March 2001 
Accepted 20 March 2001 
Correspondence to: J Mora, E-mail: MoraJ@MSKCC.org
British Journal of Cancer (2001) 85(2), 182–189
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.1849, available online at http://www.idealibrary.com on  http://www.bjcancer.comtime of diagnosis (prior to any cytotoxic therapy) and subsequently at
the time of ‘second-look’ surgery, after the 3rd or 4th round of
chemotherapy. In 6 patients, cell lines established from tumour
samples were also studied. 
All tumour specimens were reviewed by the same pathologist
(WG) for tumour cell content and histology. All patients were
staged according to the International Neuroblastoma Staging
System (INSS) (Brodeur et al, 1993) and tumour histology
scored according to the Shimada classification (Shimada et al,
1984). Standard treatment consisted of surgical resection for
patients with local-regional disease (stages 1, 2 and 3) and the
use of N6 or N7 multimodality protocols for patients with stage 4
disease as previously described (Kushner et al, 1994; Cheung
et al, 1999). 
DNA content analysis 
15 samples from a group of multiply recurred LR NB patients over
1 year of age were analysed for DNA ploidy. In 4 patients speci-
mens from diagnosis and subsequent recurrences were available
whereas in 2 patients only multiple relapsed post-chemotherapy
specimens were available. 
DNA and chromosomal content was analysed by 3 different
techniques: (a) classical G-banding karyotype described
according to ISCN (1985) where abnormal clones were defined
as 2 or more metaphase cells with identical structural
and/or numerical abnormalities, (b) interphase FISH using LSI
MYCN DNA probe (Vysis, Inc Vysis Inc, Downers Grove, IL)
and chromosome 8, 11 and 17 centromere probes to confirm
aneuploidy when detected with MYCN probe (Grady-Leopardi
et al, 1986; Shapiro et al, 1993; Taylor et al, 1994); and (c)
flow cytometry (FCM) DNA analysis on nuclei isolated from
paraffin sections using the method of Hedley modified (Hedley,
1989). 
Microsatellite allelic analysis 
Allelic analysis was performed as previously described (Mora 
et al, 2000) in samples with known diploid DNA index to 
avoid interpretation problems from aneuploidy. Primer
sequences for 12 polymorphic microsatellite loci on chromo-
some 1 were obtained from the Genome Data Base.
Fluorescently labelled primers were obtained from Research
Genetics (AL). 
PCR products were initially analysed with Genescan Software
(Applied Biosystems, Inc, Foster City, CA). For heterozygous
samples the heights of the 2 allele peaks were used to calculate
the allele ratio between the normal and tumour sample. The ratio
(R) between allele peaks was calculated dividing the largest
peak to the shortest peak, as recommended by the manufacturer
(PE). 
RESULTS 
Clonal heterogeneity and clonal evolution of tumour
DNA content 
The results of the DNA and chromosomal ploidy study are summa-
rized in Table 1. All 4 pre-chemotherapy tumour samples (cases #1,
2, 4, and 6; Table 1) available contained 2 distinct clones, one
diploid and one triploid by FISH analysis of chromosomes 2, 11
and 17. Eight tumours had a triploid chromosome 2 clone detected
by FISH, 3 of the 8 with DI>1, and 2 with hyperdiploid karyotypes.
Histologically confirmed viable post-chemotherapy tumour
samples were 100% diploid by all techniques used. 
These findings suggested that heterogeneity of tumour DNA
content and its evolution towards pure diploidy may be associated
with multiply recurrent and lethal LR NB. 
Allelotype analysis 
Genetic heterogeneity and evolution in the absence of
chemotherapy (Group 1) 
The existence of multiple clones within individual tumours was
suggested initially by the observation of tumours showing complex
patterns of allelic imbalance (AI). In some cases allelic ratios
compatible with partial or subclonal loss were present in samples that
exhibited complete loss of heterozygosity at adjacent loci. In other
cases, ratios for one microsatellite marker varied among multiple
samples from a patient when other allele ratios were maintained. By
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Table 1
Pt# Tumour# Timing Stage  Triploid Chr. 2* % DI Karyotype 
1 1601 Diagnosis 3 85 1.55 48–65 XX del 1p36 
1610 Relapse 3 87 nd 64–70 XX del 1p36 
1868 Post-chemo 3 0 nd 46 XX 
2 reported Diagnosis 1 35 1 46, XX, tri7 
1564 Relapse 3 0 1 nd 
3 1618 Post-chemo 3 0 1 46, XY 
1820 Post-chemo 3 0 1 46 XY;45 XY, +2, –3, –5 
4 1837 Diagnosis 3 89 1.12 46, XX 
1979 Post-chemo 4 0 1 46, XX 
5 1428 Post-chemo 3 75 1.14 40–45 XX 
1512 Post-chemo 3 10 nd 44–46 XX del 1p32**
1526 Post-chemo 3 4 nd 46/40–45 XX 
1581 Post-chemo 3 0 nd 44 XX 
6 1637 Diagnosis 3 72 1 nd 
1645 Post-chemo 3 0 nd 46XXdel1p22,11q13 
*When aneuploidy was detected using LSI-MYCN probe for chromosome 2, the aneuploidy was corroborated with centromeric
probes for chromosomes 8,11 and 17. **Complete karyotype: 44–46, XX, del (1)(p32), +6, add (10)(p11), +11, add(11)
(q21),der(13)t(13;21) (p10;p10)x2, –16, 17, der(19)t (14;19) (q11;p13), der(21) t (21;22) (P10;P10) – 12 cells; 46, XX–8 cells. 184 J Mora et al 
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studying multiple tumour sites obtained at the same or sequential
surgeries, the hypothesis of clonal heterogeneity or multi-clonality
could be tested since each site may have been populated with only
one or a restricted subset of tumour cell clones. The biologic, patho-
logic and clinical characteristics of patients in group 1 are summa-
rized in Table 2. Of the 12 patients with multiple samples available
for analysis, 8 (66%) showed different patterns of allelic ratios
among their multiple tumour samples. The allelic analysis was
performed at least 3 times for each discrepancy and the mean ratio of
markers showing variability among samples are indicated in Table 2.
The ratios in 2 cases (Cases 5, 9) are suggestive of subclonal changes
in some samples with values between 0.35–0.65 indicating 30 to
60% loss or gain of one allele (see Table 2). In other samples of these
same cases, the alleles were either retained (average index ratio 0.9 to
1.1) or there was more complete loss of heterozygosity demonstrated.
The non-identity of LOH patterns among samples collected in the
absence of selective pressure from chemotherapy – and with compa-
rable amounts of estimated tumour cell content – suggest that allelic
imbalance heterogeneity was part of the malignant process de novo. 
In this group, 3 of 12 patients had heterogeneous patterns of
microsatellite mutation (MM) at multiple chromosome 1 loci
(Cases 1, 4, 12; Table 2). The significance of MM in these samples
is not known but may reflect the instability of short tandem repeats
in these tumours. 
Clonal heterogeneity and evolution following chemotherapy
(group 2) 
When paired tumour samples before and after chemotherapy were
analysed, allelic discordance or clonal change following
chemotherapy was present in 6 of 10 samples (Table 3). Four
samples  had LOH only in the pre-treatment sample (cases 2, 4, 8, 10;
Table 3) with retention of heterozygosity or normalization of allelic
ratio post therapy (Figure 1). Further evidence was provided by
case #10 (Table 3) where deletions of markers on 1p36 identified
at diagnosis were no longer detectable on the 2nd look surgery
specimen. However, at the time of relapse, the original pattern of
deletion was again detectable (see Figure 2). We interpret these
findings to mean that clones with LOH were preferentially elimi-
nated by chemotherapy, and might have growth advantage when
compared to clones with intact alleles. However, we did not find a
consistent locus of allelic change following chemotherapy that
would implicate specific regions of chromosome 1 in chemosensi-
tivity. 
In 3 of the 10 pairs of samples from group 2, cases #4, 6, 10, the
diagnostic and 2nd-look specimens (Table 3) had MM as evolving
clonal elements. The non-germline alleles disappeared following
chemotherapy in all the cases (Figure 3). Despite losing the
mutated alleles in the 2nd look specimen, identical MM patterns
emerged in the relapse specimen of case #10. 
Clonal pattern and metastasis 
Loss of heterozygosity at 2 regions, 1p36 and 1p22 were associ-
ated with clinical stage in our previous study (Mora et al, 2000). To
evaluate if clonal changes in vivo correlated with distant metas-
tasis, we compared the patterns of LOH at 1p36/1p22 in 9 primary
tumours versus metastases to regional lymph nodes (T#1637,
1313, 1520) or distant organs (lung: T#1635; renal hilum: T#1642;
CNS: T#1596; skin: T#1437; liver: T#1840 and #877) (see Table 4).
4 showed discordant LOH in the consensus region of loss for 1p36
(D1S548 to D1S511) and 5 exhibited discordant LOH in the
consensus region of loss for 1p22 (D1S481 to D1S2627).
Although the number of cases analysed is small, there was no
consistent change in the pattern of 1p22 or 1p36 LOH among
metastatic samples. 
Clonal pattern between primary and derived cell-lines 
In vivo tumours were compared to derived cell lines from bone
marrow relapses for 6 patients (Table 5). In case #1, we analysed
original tumour and recurrence, and derived cell lines from both
(CL-1 and CL-2 in Table 1). Patterns of allelic imbalance differed
from those of the original tumours for both cell lines. All cell lines
showed more extensive regions of LOH compared to their original
tumours suggesting either survival advantage or predisposition to
LOH in vitro. Changes in the MM patterns were also observed
with similar implications: loci of MM in the original tumour
became sometimes regions of LOH while new mutations were
acquired in other regions of chromosome arm 1p in derived cell
lines passaged in vitro. 
DISCUSSION 
Chromosome 1p LOH is a common event in NB and the pattern of
losses has been correlated with clinical categories of the disease
(Mora et al, 2000). The high incidence of deletions and the fact
that both low and high stages of disease share this mutation,
suggests that 1p LOH is an early event in the tumorigenesis of NB.
Therefore LOH at 1p could be viewed as an event that confers
selective advantages for continual cell replication and growth of
the deleted cell clone. Changes in normal diploid DNA content are
common findings among LR NB and are viewed as early events
for this subgroup of NB (Mora et al, 2001). The evolution of these
clones can be tracked by studying multiple tumour sites or
multiple samples over time. 
Prior studies have shown intratumoral genetic heterogeneity in
sporadic NB cases using different biological markers including 1p
LOH,  MYCN and ploidy (Ambros et al, 1995; Brodeur, 1995;
Gotoh et al, 1998). The analysis of changes in DNA ploidy over
time in a selected group of relapsed LR NB showed that hetero-
geneity of tumour DNA ploidy and clonal evolution towards
diploidy, probably related to the selective pressure of chemo-
therapy, was common. Furthermore the evolution towards diploidy
was highly correlated with recurrence and lethality in this unusu-
ally aggressive subgroup of LR NB. In this regard, the widely held
assumption, for DNA index profiles of nuclei from tumour
samples that in the presence of a hyperploid peak the diploid peak
reflects non-tumoral origin (Hedley, 1989), may not be true for
NB. Due to the high degree of genetic heterogeneity in vivo it
seems imperative to use a tumour marker besides DNA index to
establish the origin of individual cells or clones. 
These initial findings prompted us to a more detailed study of
clonal heterogeneity in a larger series of patients with a very sensi-
tive molecular technique. We used patterns of chromosome 1
allelic imbalance and mutation to study de novo and acquired
genetic heterogeneity in individual NB samples. The use of fluo-
rescent technology to analyse microsatellite sequences has made it
easier to identify and quantitate allele bands (Cawkwell et al,
1993; Larson et al, 1997) and provides considerable advantages
over conventional approaches: (a) it allows the visualization of
alleles using an electropherogram which simplifies its recognition;
and (b) uses an internal standard based on size allowing a precise
evaluation of repeat length differences. Using this technology we
analysed over 3000 genotypes for LOH on chromosome 1 of 180G
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Table 2 Comparison of tumours collected from different sites or times (group 1) 
1p36.3 35 35 34.1 31 31 22 22 22 21 1qtel 1qtel 
Pt# Sample Site TCC STAGE PLOIDY MYC-N D1S548 D1S592 D1S552 D1S511 MycL D1S1669 D1S1596 D1S2766 D1S1618 D1S1673 D1S1602 D1S547 
1 755-Dx retroperitoneum 100% LR (2) 1 NA 1.64 H 3.4 H 1.05 1.1 MM H 1.1 + H 
1252-rel retroperitoneum 80% 1.76 H 0.9 H 1.2 – H + 1.6 + H 
2 1386-Dx adrenal T. 100% 4 1 A H H – H – H + + – H + + 
1635-rel lung T. 90% H H – H – H + + – H + + 
3 1631-Dx adrenal T. 80% 4 1 NA + H + H + + + + + + + + 
1642-rel renal hilium T. 80% + H + H + + + + + + + + 
1896-rel 80% + H + MM MM + + + + +
4 1369-Dx adrenal T. 70% 4 1 NA MM + H 0.1 MM MM 1 MM MM – + MM 
1596-rel CNS T. 80% MM + H 1 + MM 0.1 H – – + + 
5 1428-rel colon T. 80% LR (3) 1.1 NA H H + + + + + 0.2 MM + + + 
1439-rel pelvic T. 70% H H + + 0.5 + + 0.2 MM + + + 
1512-rel pelvic T. 70% H H + + 1 + + 1 MM + + + 
1526-rel retroperitoneal T. 70% H H + 1.2 + + 1 0.2 + +  +
1563-rel retroperitoneal T 90% H H + + 1.03 + + 1 + + +  +
1581-rel retroperitoneal T 90% H H + + 1.2 + + 1 MM + + + 
6 1127-rel neck LN 100% 4n 1 NA + + H H – – 2 + – H + H 
1397-rel neck LN 100% + + H H – – 1.1 + – H + H 
96-rel neck LN 100% + + H H – – 1 + – H + H 
7 1637-Dx cervical LN 70% LR (3) 1 NA H + + + + H + + H H + 
1643-Dx epidural T 60% H + + 0.8 + H + + H H + – 
8 1377-Dx adrenal T. 100% 4 1.04 A + + H + + + + + 1.4 + + + 
1437-Dx skin abdomen 80% NA + + H + + + + + 1.6 + + + 
9 1312-Dx mediastinal T. 100% 4 1 NA + – – – H + + – H 1.5 2 H 
1313-Dx Richest wall LN 100% + – – – H + + – MM 1.6 2 H 
1314-Dx Diaphragma LN 100% + – – – H + + 1.1 1 H 
1315-Dx Lichest wall LN 100% + – – – H + + 1.6 2 H 
10 1841-Dx Adrenal T. 90% 4 1 NA – 2 0.3 H + 0.7 0.8 + – – + + 
1840-Dx liver 80% – 0.9 0.9 H + 1.9 1.8 – – – + + 
11 1434-2nd spinal T. 70% 4 1 NA – + + + + H + + H – H + 
1435-2nd primary T. 80% – + + + + H + + H – H + 
1520-2nd axillary LN 80% – + + + + H + + H – H + 
12 877-rel Liver nodule 70% 4 1 A – MM 1 – + MM MM MM + MM H MM 
878-rel adrenal T. 50% A – – 0.1 – + MM MM MM + MM H MM 
Dx=sample at diagnosis; rel = sample at relapse; 2nd = sample taken during active course of chemotherapy. T = tumour; LN = lymph node; TCC = tumour cell content;: LR = local-regional disease (INSS stages 1,2 or
3). 4 = INSS stage 4; 4n = INSS stage 4n; NA = non amplified; A = amplified. + = retained heterozygosity; –  = LOH; H = non informative; MM = microsatellite mutation; Discordances are shaded grey. Numbers in the
table are allelic ratios for discordant samples. 1
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Table 3 Comparison of tumours before and after chemotherapy (Group 2) 
1p36.3 35 35 34.1 31 31 22 22 22 21 1qtel 1qtel 
Pt# Sample Site TCC STAGE PLOIDY MYC–N D1S548 D1S1592 D1S552 D1S511 MycL D1S1669 D1S1596 D1S2766 D1S1616 D1S1673 D1S1602 D1S547 
1 1129–Dx liver 90% 4 1 NA H + + + – + H + H 
1147–2nd adrenal T. 80% H + + + – + H + + + + H 
2 1012–Dx portal LN 75% 4 1 A H H H H 0.1 0.1 0.1 0.1 H 0.1 0.1 H 
1035–2nd adrenal T. 75% H H H H 1 1 1 1 H 1 1 H 
3 1419–Dx abdominal LN 90% 4 1 NA H + + + MM + H + 1 + MM + 
1466–2nd retroperitoneal T 70% H + + + + + H + 0.1 + + + 
4 1452–Dx adrenal T. 4 1 NA H H + + H + + + 0.1 + + + 
1523–2nd adrenal T. 100% H H + + H + + + 1 + + + 
1524–2nd pelvic T 90% H H + + H + + + 1 + + + 
5 1828–Dx mediastinal T 75% 4 1 NA + + + + + H H + H + H + 
1855–2nd mediastinal T 100% + + + + + H H + H + H + 
6 1647–Dx abdominal T 70% 4 1 NA MM + MM H MM MM MM 1 0.1 MM MM 1.6 
1844–2nd abdominal T 80% H + + H + + + 0.3 1 + + 1.2 
1845–2nd abdominal T 70% H + + H + + + – 1 + + 1.1 
7 1827–Dx retroperitoneal T. 80% 4 1 NA H H + + + + + + + + + + 
1852–2nd adrenal T. 90% H H + + + + + + + + + + 
1853–2nd celiac LN 70% H H + + + + + + + + + 
8 1267–rel pandreatic T. 60% 4 1 NA H H H + + + 0.1 + H 1 + + 
1270–2nd liver 70% H H H + + + 1 + H 1 + + 
1623–rel cervical T. H H H + + – 1 + H 0.2 + + 
9 1517–rel retroperitoneal T. 70% 4 1 A H – – – – + + + + + – + 
1565–2nd retroperitoneal T. 80% H – – – – + + + + + – + 
10 1130–Dx inguinal LN 70% 4 1 NA + 0.3 0.4 MM MM 0.9 MM 0.3 + 0.6 0.4 MM 
1170–2nd adrenal T. + 0.8 0.7 + + 0.9 H 0.6 + 0.8 0.8 + 
1436–rel paraspinal T. 50% + 0.2 0.2 MM MM 0.3 MM 0.1 – 0.4 0.9 MM 
Dx = sample at diagnosis; rel = sample at relapse; 2nd = sample taken during active course of chemotherapy. T = tumour, LN = lymph node; TCC = tumour cell content;: LR = local–regional disease (INSS stages 1,2
or 3). 4 = INSS stage 4; 4n = INSS stage 4n; NA = non amplified; A = amplified. +=retained heterozygosity; – = LOH; H = non informative; MM = microsatellite mutation; Discordances are shaded grey. Numbers in the
table are allelic ratios for discordant samples. Genetic heterogeneity in neuroblastoma 187
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NB tumours from 120 patients (Mora et al, 2000). During this
analysis MM phenotype defined as mutations affecting more than
30% of markers was identified in 20 (16%) of the 120 NB patients.
Further characterization established that mutations within this
group were more frequent in tri-and tetra-nucleotide repeats, and
occurred at multiple loci, but was most often detected in chromo-
somal regions previously identified as frequently loss in NB. MM
tumours were also analysed with 12 microsatellite markers
mapping to 4 different chromosomes. A consistent pattern of more
than 30% of markers mutated was observed all throughout the
genome regardless of the type of marker (di-, tri- or tetra-
nucleotide) or the chromosome location. In all cases there was at
least 30% preservation of other polymorphic alleles for matched
samples. Our somewhat higher incidence of MM compared to
previous reports in NB (Martinsson et al, 1995) may be explained
by increased sensitivity and the use of more tetranucleotide repeat
markers compared to prior studies. After amplification by PCR,
each allele is detected as a predictable component of a complex
signature that can be followed over time or among multiple
tumour sites. We analysed a series of patients with tumour samples
of known diploid DNA content to avoid interpretation problems.
Samples were collected over time to follow spontaneous or
therapy related molecular evolution and from different sites to
study the clonal composition of metastatic foci. We found intra-
tumoral heterogeneity using chromosome 1 AI and MM patterns
to be common. For these patients individual tumour samples were
genetically related but not identical, and clonal populations spon-
taneously evolved during tumour progression. 
Although we found intratumor clonal heterogeneity and clonal
evolution in vivo over time, we did not detect a consistent pattern
of accumulation of chromosome 1p changes in the evolution of
multiply relapsed specimens in the absence of therapy. This
suggests 1p LOH is not a mutation driving the progression of
tumours with acquisition of more aggressive phenotypes in late
stages of disease. In vitro cell lines established from tumours
however showed larger and more widespread 1p mutations. These
findings suggest that in vitro selective pressure may differ signifi-
cantly from in vivo selective pressures such as microenvironment,
immune surveillance and genetic background. 
Our data suggest that clonal genetic populations can be
selected for by cytotoxic therapy. The disappearance of aneu-
ploid clones and clones with 1p LOH during chemotherapy, and
in one case the reappearance of the same 1p-deleted clones at
relapse, would suggest that in this case 1p-deleted clones were
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Figure 1 Representative electropherograms. N is analysis of DNA from
normal tissue and Dx/2nd is from tumour samples taken at diagnosis or at
second-look surgery respectively. There is LOH for marker D1S548 at 1p36
with ratio close to 0 in the sample from diagnosis and 1.65 in the second-
look surgery sample and a nearby marker, D1S1592 on 1p36, shows LOH
with a ratio close to 0 in the diagnostic specimen and 0.52 in the second-look
specimen 
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Figure 2 Representative electropherograms for Case #10, Table 3. N is
analysis of DNA from normal tissue and Dx/2nd/rel is from tumour samples
taken at diagnosis, at second-look surgery and at relapse respectively. The
analysis of D1S1592 marker on chromosome 1p36 is shown. The ratios for
each tumour sample compared to the normal tissue show LOH at diagnosis
(2.07) and relapse (4.35) specimens and retention of heterozygosity ratio
(1.03) for the second-look surgery specimen 
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Figure 3 Representative electropherograms for Case #6, Table 3. N is
analysis of DNA from normal tissue and Dx/2nd is from tumour samples
taken at diagnosis and second-look surgery respectively. The analysis of
MycL marker on chromosome 1p31 is shown. MM is detected for MycL only
in the diagnostic sample compared to normal pattern and 2nd-look surgery
specimen patterns 188 J Mora et al 
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more sensitive to cytotoxic treatments than 1p-intact ones.
Differential proliferative rates may explain their different
chemosensitivity. Whether new 1p deletions were acquired at
relapse, or whether the original 1p-deleted clones regrew during
clinical relapse is an open and important question. A better
understanding of the evolution of such subclones and their
Table 5 Comparison of in vivo tumour sample with derived cell lines 
1p36.3 1p35 1p35 1p34.1 1p31 1p31 1p22 1p22 1p22 1p21 1qtel 1qtel 
Pt# Sample D1S548 D1S1592 D1S552 D1S511 MycL D1S1669 D1S1596 D1S481 D1S2766 D1S1673 D1S1602 D1S547 
1 755–Dx 1.6 H 3.4 H 1.05 1.17 MM + H 1.1 + H 
1252–rel 1.7 H 0.9 H 1.2 – + H 1.6 + H 
CL–1 1 H 0.9 H 1.2 1.1 – + 1.7 + H 
CL–2 MM MM 0.1 H 0.1 0.1 – 0.1 MM MM MM 
2 1386–Dx H H 0.1 H 0.2 H + + + H + + 
1635–rel H H 0.2 H 0.3 H + + + H + + 
CL H H MM H + + + MM 
3 1428–rel 1 H H + + + + + + 0.2 + + + 
1439–rel 2 H H + + 0.5 + + + 0.2 + + + 
1512–rel 3 H H + + 1 + + + 1 + + + 
1526–rel 4 H H + 1.2 + + + 1 + + + 
1563–rel 5 H H + + 1.03 + + + 1 + + + 
1581–rel 6 H H + + 1.2 + + + 1 + + + 
CL H MM + MM 0.1 0.1 0.1 + + 0.1 0.1 + 
4 827–Dx 0.1 0.2 MM MM + MM MM 0.2 MM + 0.2 MM 
CL 0.1 0.2 0.1 MM 0.1 MM 0.1 MM + MM MM 
5 1876–Dx H H 0.1 0.1 0.1 0.1 + 0.2 0.1 + H 
CL H H 0.2 0.3 0.2 0.2 + 0.1 0.1 + H 
6 1172–rel + + + + + + + H + + + H 
CL 0.1 0.1 0.1 0.1 0.1 MM MM + MM 0.1 + MM 
Dx = sample at diagnosis; rel = sample at relapse; 2nd = sample taken during active course of chemotherapy. T = tumour; LN = lymph node; TCC = tumour cell
content; LR = local–regional disease (INSS stages 1,2 or 3). 4 = INSS stage 4; 4n = INSS stage 4n; NA = non amplified; A = amplified. += retained
heterozygosity; –= LOH; H = non informative; MM = microsatellite mutation; Discordances are shaded grey. Numbers in the table are allelic ratios for discordant
samples. 
Table 4 Comparison of primary tumour and distant metastases 
1p36.3 35 35 34.1 22 22 22 21 21 
Pt# Sample Primary/distant TCC D1S548 D1S1592 D1S552 D1S511 D1S481 D1S2766 D1S1618 D1S1673 D1S2627
organ
1 1386–Dx adrenal T. 100% H H – H + + – H + 
1635–rel lung T. 90% H H – H + + – H + 
2 1631–Dx adrenal T. 80% + H + H + + + + + 
1642–rel renal hilium T. 80% + H + H + + + + + 
3 1369–Dx adrenal T. 70% MM + H – + MM MM – MM 
1596–rel CNS T. 80% MM + H + – H – – H 
4 1377–Dx adrenal T. 100% + + H + + + + + MM 
1437–prg skin abdomen 80% + + H + + + – + MM 
5 1841–Dx Adrenal T. 90% – – – H + + – – – 
1840–prg liver 80% – + + H + – – – – 
6 878–rel adrenal T. 50% – – – – – MM + MM + 
877–rel Liver nodule 70% – MM + – – MM + MM + 
Primary/regional  LN
7 1643–Dx epidural T 60% H + + + + + H H + 
1637–Dx cervical LN 70% H + + + + + H H + 
8 1312–Dx mediastinal T. 100% + – – – H – H – + 
1313–Dx R/chest wall LN 100% + – – – H – MM – + 
9 1435–2nd primary T. 80% – + + + H + H – + 
1520–2nd axillary LN 80% – + + + H + H – + 
Dx = sample at diagnosis; rel = sample at relapse; 2nd = sample taken during active course of chemotherapy. T = tumour; LN = lymph node; TCC = tumour cell
content;: LR = local–regional disease (INSS stages 1,2 or 3). 4 = INSS stage 4; 4n = INSS stage 4n; NA = non amplified; A = amplified. + = retained
heterozygosity; – = LOH; H = non informative; MM = microsatellite mutation; Discordances are shaded grey. Numbers in the table are allelic ratios for discordant
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response to treatment may be critical in the future design of cura-
tive strategies. The molecular characterization of these tumour
clones, and their correlation with histologic subtypes may
provide clinical insights in the molecular staging and prognosti-
cation of neuroblastoma. 
The accumulation of genetic abnormalities has been suggested as
a mechanism for the development of metastatic capability (Fearon
and Vogelstein, 1990). Recent reports on NB have identified
differing biological features at primary and metastatic sites,
implying clonal selection for some biological markers in metastasis
(Suzuki et al, 1997; Gotoh et al, 1998). In our study, the comparison
of 1p LOH patterns between original tumour sites and metastasis in
lymph nodes or distant organs did not reveal any preferential 1p
loss. Although clonal heterogeneity was common between sites, we
did not find a consistent increase in number or size of deletions in
metastatic samples. Other studies have shown similarly an absence
of changes in MYCN amplification or ploidy between primary and
metastatic sites (Brodeur et al, 1987; Taylor et al, 1988). Our results
would suggest that the ability of tumours to metastasize is deter-
mined by genetic features other than 1p LOH. 
Since non-progressing NB tumours were not analysed because
of the lack of material and evolution, the data presented demon-
strates that intratumoral clonal heterogeneity is a common part of
the malignant process de novo in progressing NB tumours. More
importantly, there appears to be genetic selection during cytotoxic
therapy that may reflect differences in chemosensitivity among the
different clones. Such information might be useful for predicting
response and tailoring therapy for individual patients. 
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